Trial Profile
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Mibavademab (Primary) ; Mibavademab (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 24 Mar 2023 Results evaluating Mibavademab pharmacokinetics, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 06 Mar 2020 Status changed from recruiting to completed.
- 13 Nov 2019 Planned End Date changed from 6 Oct 2019 to 27 Jan 2020.